This CME initiative is designed to meet the educational needs of medical oncologists, surgeons, ONS nurses, and other healthcare providers involved in the treatment of patients with breast cancer.
Breast Cancer
1. | Review the cellular pathways that influence estrogen-receptor activity and resultant breast-cancer pathogenesis; | 2. | Discuss the mechanisms of action of CDK 4/6 inhibitors and the resultant anti-tumorigenic effects in hormone-positive breast cancer; |
3. | Assess the clinical trial data for both approved and investigational CDK 4/6 inhibitors for patients with HR+, HER2 negative advanced or metastatic breast cancer. |
1. | Review the cellular pathways that influence estrogen-receptor activity and resultant breast-cancer pathogenesis; |
2. | Discuss the mechanisms of action of CDK 4/6 inhibitors and the resultant anti-tumorigenic effects in hormone-positive breast cancer; |
3. | Assess the clinical trial data for both approved and investigational CDK 4/6 inhibitors for patients with HR+, HER2 negative advanced or metastatic breast cancer. |
Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 5.0+ for Mac OSX 10.5 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |